First Report *Cfr* and *OptrA* Co-harboring Linezolid-Resistant *Enterococcus faecalis* in China

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Qingqing Chen^{1,2}
Dandan Yin^{1,3}
Pei Li^{1,3}
Yan Guo^{1,3}
Desong Ming²
Yuling Lin²
Xiaoli Yan²
Zhishan Zhang²
Fupin Hu^{1,3}

¹Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, People's Republic of China; ²The Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, People's Republic of China; ³Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, People's Republic of China

Correspondence: Zhishan Zhang
Departments of Clinical Laboratory, The Affiliated Quanzhou First Hospital of Fujian Medical University, No. 248 East Street, Quanzhou City, Fujian Province 362002, People's Republic of China
Tel +86-595-22277352
Fax +86-595-22278131
Email 15859775058@139.com

Fupin Hu
Institute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Road, Shanghai 200040, People's Republic of China
Tel +86-21-52888186
Fax +86-21-62488290
Email hufupin@fudan.edu.cn

Abstract: A linezolid-resistant *E. faecalis* strain harboring *optrA* and *cfr* resistance genes were isolated from a patient in china, which had no mutations in *rplC*, *rplD*, *rplV*, and 23S rRNA gene. Transformation indicated that *optrA* and *cfr* were located on two different plasmids and both could be transferred to recipient strain, resulting in the increase of MICs of linezolid and chloramphenicol. *Cfr*, carried by an 11,872-bp plasmid, was enclosed with an *IS110* transposase in upstream and an IS3-like transposase in downstream, while *optrA* was on an 8357-bp plasmid. As far as we know, this is the first report of an *E. faecalis* clinical strain co-harboring *optrA* and *cfr* in China.

Keywords: *E. faecalis*, linezolid, *cfr*, *optrA*

Linezolid is considered as a last resort drug for the treatment of severe infections caused by multidrug-resistant gram-positive pathogens including vancomycin-resistant *Enterococcus spp.* (VRE), methicillin-resistant *Staphylococcus spp.* and *Streptococcus pneumoniae*.¹ Although most of gram-positive cocci remain susceptible to linezolid, resistant isolates of *Enterococci* have been reported worldwide. The main resistance mechanisms of *Enterococcus spp.* to linezolid include the mutation of 23S rRNA gene,² acquired resistance genes such as *cfr*, *cfr(B)*, *optrA* or *poxtA*,^{3,4} and mutation of ribosomal proteins coding genes like *rplC*, *rplD*, and *rplV*.⁵ The *cfr* and *cfr(B)* genes encode a rRNA methyltransferase causing resistance of oxazolidinones, chloramphenicols, tetracycline, lincomycins, pleuromutilin, and streptogramin A and decreasing sensitivity of macrolide.^{3,4,6-9} *Cfr* or *cfr(B)* and *optrA*, *poxtA* along with *optrA* has been previously reported on the same plasmid in *E. faecalis*, *Staphylococcus sciuri*, or *Enterococcus spp.* from swine and farm environment.¹⁰⁻¹³ Here, we firstly reported the emergence of linezolid-resistant *E. faecalis* clinical strain with *cfr* and *optrA* in China.

E. faecalis strain EF02 was isolated from the midstream urine of a 72-year-old patient with diabetes during hospitalization in November, 2018. Prior to the isolation of *E. faecalis* strain EF02, isepamicin was used for the treatment of infection. Bacterial identification was conducted by MALDI-TOF (VITEK MS, BioMérieux). Antimicrobial susceptibility testing was performed by broth microdilution according to CLSI guideline.¹⁴ *E. faecalis* strain EF02 was resistant to linezolid (MIC =8 mg/L), nitrofurantoin (MIC =64 mg/L), tetracycline (MIC =64 mg/L), erythromycin (MIC =64 mg/L), chloramphenicol (MIC =64 mg/L) and levofloxacin (MIC =32 mg/L). However, this strain was susceptible to vancomycin (MIC =1 mg/L), teicoplanin (MIC =0.5 mg/L), and ampicillin (MIC =2 mg/L). PCR detection and

Table 1 MICs for *E. Faecalis* EF02, Transformants, and the Recipient Strains (µg/ML)

Antimicrobial Agents	<i>E. faecalis</i> EF02	L13/ <i>optrA</i>	L18/ <i>cfr</i>	<i>E. faecalis</i> OG1RF
Linezolid	8	8	8	1
Tetracycline	>64	0.25	0.25	0.25
Erythromycin	>64	4	8	2
Chloramphenicol	>64	8	8	2

sequencing revealed that *E.faecalis* strain EF02 was positive for *cfr* and *optrA* without mutation among *rplC*, *rplD*, *rplV* and 23S rRNA gene. The plasmids extracted from the donor strain *E.faecalis* EF02 were then guided into the recipient strain *E.faecalis* OG1RF by the electrotransformation method.^{3,4} The transformants were selected on brain heart infusion agar containing 3 mg/L linezolid and 10 mg/L chloramphenicol. Colonies that grew on these selective plates were further confirmed by antimicrobial susceptibility testing and PCR for the detection *cfr* and *optrA* genes. Transformants harboring the

plasmid with *optrA* and *cfr* were named L13/*optrA* and L18/*cfr*, respectively. Comparing with the recipient strain, the linezolid and chloramphenicol MICs of transformants increased 4–8 fold (Table 1).

PCR mapping according to plasmid DNA sequencing of the L18/*cfr* plasmid suggested that an IS110 transposase was located upstream of *cfr* and an IS3-like transposase was located downstream of *cfr*. Mobile elements like these might lead to the transfer of resistance genes among plasmids. L18/*cfr* plasmid contained eight open reading frames encoding Y111, IS110, *cfr*, IS3, RepB, RepB, EATX, and YOEC (Figure 1). However, L13/*optrA* plasmid, which contained three open reading frames encoding ERMA, YDIF, and *optrA* (Figure 2). The result of multilocus sequence typing indicated that *E.faecalis* strain EF02 belonged to ST 330. The DNA sequencing of plasmid pEF-L18/*cfr* and pEF-L13/*optrA* has been submitted to the NCBI database (NCBI number: MT874923 and MT874924).

cfr and *optrA* genes have been reported in various gram-positive bacteria, they can be transferred to recipient bacteria by transformation experiments and cause an

Figure 1 Circular representation of the L18/*cfr* plasmid. Moving from inside to outside in the plasmid circular map, slots 1–3 (slot 1, GC skew; slot 2, GC content; slot 3, open reading frames: Y-family DNA polymerase Y111, IS110 family transposase, *cfr*, IS3 family transposase, two replication protein RepB, antitoxin epsilon EATX, Probable integrase YOEC.).

Figure 2 Circular representation of the L13/optrA plasmid. Moving from inside to outside in the plasmid circular map, slots 1–3 (slot 1, GC skew; slot 2, GC content; slot 3, open reading frames: 23S rRNA adenine(2058)-N(6)-methyltransferase ERMA, Putative ATP-binding protein YDIF, optrA).

increase in the MIC values of linezolid and chloramphenicol.^{3,4,15} The *cfr* and *optrA* located on one same plasmid in a strain have been reported. Fan R and Morroni G et al reported *Staphylococcus sciuri* isolated from pig origin in Germany and *E. faecium* isolates in Italy carrying both *cfr* and *optrA*.^{9,16} However, no conjugant or transformant was acquired to demonstrate the resistance mediated by *cfr* or *optrA*. Li et al also reported co-producing *cfr* and *optrA* of *Staphylococcus sciuri*, and got the transformant with *optrA*.¹¹ Similarly, two *E. faecium* clinical isolates carrying *cfr* and *optrA* were collected in Italy, in which *optrA* was transferred from donor to recipient, whereas *cfr* was not transferrable.¹⁷

In our study, we found *cfr* and *optrA* genes carried by *E. faecalis* EF02 were located on two different plasmids, and both plasmids could be transferred from the donor strain to the recipient by transformation experiments, making an increase of MICs of linezolid and chloramphenicol. To our knowledge, this is the first report of linezolid-resistant *E. faecalis* co-producing *cfr* and *optrA* in a clinical isolate in China.

Abbreviations

VRE, vancomycin-resistant *Enterococcus spp.*

Ethics Approval and Consent to Participate

The study was approved by the Ethics Board of Fujian Medical University.

Consent for Publication

Not applicable.

Funding

This study was supported by the Science and Technology Project of Quanzhou (2019N030S) and China Antimicrobial Surveillance Network (WI207259). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

Disclosure

The authors declare that they have no competing interests.

References

1. Sadowy E. Linezolid resistance genes and genetic elements enhancing their dissemination in enterococci and streptococci. *Plasmid*. 2018;99:89–98.
2. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. *Antimicrob Agents Chemother*. 2010;54(2):742–748. doi:10.1128/AAC.00621-09
3. Liu Y, Wang Y, Schwarz S, et al. Transferable multiresistance plasmids carrying cfr in *Enterococcus* spp. from swine and farm environment. *Antimicrob Agents Chemother*. 2013;57:42–48. doi:10.1128/AAC.01605-12
4. Wang Y, Lv Y, Cai J, et al. A novel gene, *optrA*, that confers transferable resistance to oxazolidinones and phenicols and its presence in *Enterococcus faecalis* and *Enterococcus faecium* of human and animal origin. *J Antimicrob Chemother*. 2015;70:2182–2190. doi:10.1093/jac/dkv116
5. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. Assessment of linezolid resistance mechanisms among *Staphylococcus epidermidis* causing bacteraemia in Rome, Italy. *J Antimicrob Chemother*. 2010;65:2329–2335. doi:10.1093/jac/dkq331
6. Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in *Staphylococcus sciuri*. *Antimicrob Agents Chemother*. 2000;44:2530–2533. doi:10.1128/AAC.44.9.2530-2533.2000
7. Vester B. The cfr and cfr-like multiple resistance genes. *Res Microbiol*. 2018;169:61–66. doi:10.1016/j.resmic.2017.12.003
8. Antonelli A, D'Andrea MM, Brenciani A, et al. Characterization of *poxtA*, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin. *J Antimicrob Chemother*. 2018;73:1763–1769. doi:10.1093/jac/dky088
9. Fan R, Li D, Fessler AT, Wu C, Schwarz S, Wang Y. Distribution of *optrA* and *cfr* in florfenicol-resistant *Staphylococcus sciuri* of pig origin. *Vet Microbiol*. 2017;210:43–48. doi:10.1016/j.vetmic.2017.07.030
10. Kuroda M, Sekizuka T, Matsui H, et al. Complete genome sequence and characterization of linezolid-resistant *enterococcus faecalis* clinical isolate KUB3006 carrying a *cfr(b)*-transposon on its chromosome and *optrA*-Plasmid. *Front Microbiol*. 2018;9:2576. doi:10.3389/fmicb.2018.02576
11. Li D, Wang Y, Schwarz S, Cai J, Shen J. Co-location of the oxazolidinone resistance genes *optrA* and *cfr* on a multiresistance plasmid from *Staphylococcus sciuri*. *J Antimicrob Chemother*. 2016;71:1474. doi:10.1093/jac/dkw040
12. Lazaris A, Coleman DC, Kearns AM, et al. Novel multiresistance *cfr* plasmids in linezolid-resistant methicillin-resistant *Staphylococcus epidermidis* and vancomycin-resistant *Enterococcus faecium* (VRE) from a hospital outbreak: co-location of *cfr* and *optrA* in VRE. *J Antimicrob Chemother*. 2017;72:3252–3257.
13. Hao W, Shan X, Li D, et al. Analysis of a *poxtA*- and *optrA*-co-carrying conjugative multiresistance plasmid from *Enterococcus faecalis*. *J Antimicrob Chemother*. 2019;74:1771–1775. doi:10.1093/jac/dkz109
14. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing*, 30th ed. Wayne, PA: CLSI supplement M100. Clinical and Laboratory Standards Institute; 2020.
15. Shen J, Wang Y, Schwarz S. Presence and dissemination of the multiresistance gene *cfr* in Gram-positive and Gram-negative bacteria. *J Antimicrob Chemother*. 2013;68:1697–1706. doi:10.1093/jac/dkt092
16. Morroni G, Brenciani A, Antonelli A, et al. Characterization of a multiresistance plasmid carrying the *optrA* and *cfr* resistance genes from an *enterococcus faecium* clinical isolate. *Front Microbiol*. 2018;9:2189. doi:10.3389/fmicb.2018.02189
17. Brenciani A, Morroni G, Vincenzi C, et al. Detection in Italy of two clinical *Enterococcus faecium* isolates carrying both the oxazolidinone and phenicol resistance gene *optrA* and a silent multiresistance gene *cfr*. *J Antimicrob Chemother*. 2016;71:1118–1119. doi:10.1093/jac/dkv438

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>